🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. LIBTAYO 350 mg concentrate for solution for infusion., matching Placebo with R2810

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  2. LIOTHYRONINE SODIUM , LEVOTHYROXINE SODIUM , Placebo tablets are white, round, biconvex tablets. The tablets contain no active pharmaceutical ingredient (API), but are manufactured following the manufacturing process of the liothyronine tablets presented in the IMPD for liotyronine 2, 2.5, 3.75, and 5 µg

    Disc Medicine

    Hypothyroidism Triiodothyronine Quality of Life Persistant complaints

    phase 3 small molecule active

    1 trial

  3. LMF237 50/250 mg

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  4. LNP023

    Novartis Pharmaceuticals

    Primary IgA Nephropathy

    phase 3 small molecule active

    1 trial

  5. LOMUSTINE, 4-L-[131I]iodo-phenylalanine, LOMUSTINE

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 3 small molecule active

    1 trial

  6. LOU064

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  7. LOU064 (blinded)

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  8. LOU064, CLINDAMYCIN , Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, LOU064, Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , -

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  9. LOU064, COLESTYRAMINE , TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  10. LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, -, -

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria (CINDU)

    phase 3 small molecule active

    1 trial

  11. LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE , Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, TERIFLUNOMIDE, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  12. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEEs)

    phase 3 small molecule active

    1 trial

  13. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEE)

    phase 3 small molecule active

    1 trial

  14. LUM

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  15. Lapatinib

    Novartis Pharmaceuticals

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  16. Lapatinib

    Novartis Pharmaceuticals

    Neoplasms, Breast

    phase 3 small molecule terminated

    2 trials

  17. Laquinimod

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    2 trials

  18. Laquinimod

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 3 small molecule terminated

    2 trials

  19. Laquinimod

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    3 trials

  20. Lenabasum 20 mg

    Corbus Pharmaceuticals Holdings

    Dermatomyositis

    phase 3 small molecule completed

    1 trial

  21. Lenabasum 5 mg

    Corbus Pharmaceuticals Holdings

    Diffuse Cutaneous Systemic Sclerosis

    phase 3 small molecule terminated

    1 trial

  22. Lerotinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  23. Levetiracetam

    UCB Pharma

    Epilepsy

    phase 3 small molecule completed

    1 trial

  24. Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets

    Teva Pharma GmbH

    Contraception

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources